Diabetes, Vol 37, Issue 2 200-203, Copyright © 1988 by American Diabetes Association

ARTICLES

Incretin effect due to increased secretion and decreased clearance of insulin in normal humans

LT Shuster, VL Go, RA Rizza, PC O'Brien and FJ Service
Department of Statistics and Epidemiology, Mayo Medical School, Rochester, Minnesota 55905.

To assess the contribution of changes in insulin secretion and clearance to the incretin effect (greater insulinemia after oral than after intravenous glucose), 10 healthy subjects were studied after oral glucose (1 g/kg body wt) and again when glucose was infused intravenously at rates to match arterialized plasma glucose concentrations after oral glucose. Although basal and integrated plasma glucose did not differ between oral and intravenous glucose, integrated responses of insulin (3.3 +/- 0.5 vs. 1.8 +/- 0.4 mU ml-1.240 min-1, P less than .001), C-peptide (456.5 +/- 58.5 vs. 327.9 +/- 46.3 ng.ml-1.240 min-1, P = .002), gastric inhibitory polypeptide, (16.8 +/- 3.5 vs. -2.8 +/- 1.0 micrograms.ml-1.240 min-1, P less than .001), and insulin secretion (6.6 +/- 1.1 vs. 4.7 +/- 0.7 U.240 min-1, P = .003) were greater with oral than intravenous glucose. However, insulin clearance, whether calculated as the molar ratio of integrated C-peptide to integrated insulin responses (6.9 +/- 0.7 vs. 14.2 +/- 3.8, P = .005) or from the formula insulin clearance equals insulin secretion divided by integrated insulin responses (1.1 +/- 0.2 vs. 2.5 +/- 0.7 L.min-1.m-2, respectively, P = .002), was less for oral than for intravenous glucose. Therefore, the incretin effect is mediated both by increased secretion and decreased clearance of insulin.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. Vollmer, J. J. Holst, B. Baller, M. Ellrichmann, M. A. Nauck, W. E. Schmidt, and J. J. Meier Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance Diabetes, March 1, 2008; 57(3): 678 - 687. [Abstract] [Full Text] [PDF]

				J. J. Meier, J. J. Holst, W. E. Schmidt, and M. A. Nauck Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E849 - E856. [Abstract] [Full Text] [PDF]

				M. Campioni, G. Toffolo, L. T. Shuster, F. J. Service, R. A. Rizza, and C. Cobelli Incretin effect potentiates beta-cell responsivity to glucose as well as to its rate of change: OGTT and matched intravenous study Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E54 - E60. [Abstract] [Full Text] [PDF]

				M. A. Nauck, B. Baller, and J. J. Meier Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes Diabetes, December 1, 2004; 53(suppl_3): S190 - S196. [Abstract] [Full Text] [PDF]

				N. N. Rudovich, H. J. Rochlitz, and A. F.H. Pfeiffer Reduced Hepatic Insulin Extraction in Response to Gastric Inhibitory Polypeptide Compensates for Reduced Insulin Secretion in Normal-Weight and Normal Glucose Tolerant First-Degree Relatives of Type 2 Diabetic Patients Diabetes, September 1, 2004; 53(9): 2359 - 2365. [Abstract] [Full Text] [PDF]

				L. Morin-Papunen, I. Vauhkonen, R. Koivunen, A. Ruokonen, H. Martikainen, and J. S. Tapanainen Metformin Versus Ethinyl Estradiol-Cyproterone Acetate in the Treatment of Nonobese Women with Polycystic Ovary Syndrome: A Randomized Study J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 148 - 156. [Abstract] [Full Text] [PDF]

				G. I. Uwaifo, S. J. Parikh, M. Keil, J. Elberg, J. Chin, and J. A. Yanovski Comparison of Insulin Sensitivity, Clearance, and Secretion Estimates Using Euglycemic and Hyperglycemic Clamps in Children J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2899 - 2905. [Abstract] [Full Text] [PDF]

				R. M. Koivunen, J. Juutinen, I. Vauhkonen, L. C. Morin-Papunen, A. Ruokonen, and J. S. Tapanainen Metabolic and Steroidogenic Alterations Related to Increased Frequency of Polycystic Ovaries in Women with a History of Gestational Diabetes J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2591 - 2599. [Abstract] [Full Text] [PDF]

				H. Kindmark, J. Pigon, and S. Efendic Glucose-Dependent Insulinotropic Hormone Potentiates the Hypoglycemic Effect of Glibenclamide in Healthy Volunteers: Evidence for an Effect on Insulin Extraction J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2015 - 2019. [Abstract] [Full Text]

				L. C. Morin-Papunen, I. Vauhkonen, R. M. Koivunen, A. Ruokonen, H. K. Martikainen, and J. S. Tapanainen Endocrine and Metabolic Effects of Metformin Versus Ethinyl Estradiol-Cyproterone Acetate in Obese Women with Polycystic Ovary Syndrome: A Randomized Study J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3161 - 3168. [Abstract] [Full Text]

				L. C. Morin-Papunen, I. Vauhkonen, R. M. Koivunen, A. Ruokonen, and J. S. Tapanainen Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome Hum. Reprod., June 1, 2000; 15(6): 1266 - 1274. [Abstract] [Full Text] [PDF]

				A. Cagnacci, A.M. Paoletti, S. Arangino, G.B. Melis, and A. Volpe Effect of ovarian suppression on glucose metabolism of young lean women with and without ovarian hyperandrogenism Hum. Reprod., April 1, 1999; 14(4): 893 - 897. [Abstract] [Full Text] [PDF]